[Special Stock] Pharmicell's Stock Soars Following US Monkeypox Emergency Declaration
![[Special Stock] Pharmicell's Stock Soars Following US Monkeypox Emergency Declaration](http://www.asiae.co.kr/news/img_view.htm?img=2016012914025477581_1.jpg)
[Asia Economy Reporter Minji Lee] Pamicell, a stock related to monkeypox, is showing a sharp rise during trading hours.
At 10:54 AM on the 5th, Pamicell was trading at 13,900 KRW, up 10.32% compared to the previous trading day.
The U.S. government's declaration of a public health emergency related to monkeypox is analyzed to have influenced the stock price. This measure aims to strengthen the federal government's response to monkeypox, which continues to see increasing infections worldwide. Currently, the number of monkeypox cases in the U.S. has surpassed 6,600 since the first case was reported in mid-May, indicating a spreading trend.
The World Health Organization (WHO) had already declared monkeypox an international public health emergency on the 23rd of last month.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Introduces New "Special Performance Bonus" for Semiconductors, Paid Entirely in Company Shares
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "US-Iran: Patch-Ups More Likely Than Settlement... Unlikely to Resolve Within 6 Months" [Economic Policy Zoom-In]
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Since 2007, Pamicell has been the exclusive supplier of HDP-Tosylate, a key intermediate used in the smallpox treatment drug 'Brincidofovir' being developed by the U.S. biotech company Chimerix.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
